NEW YORK (GenomeWeb News) – Proteomics firm ProteoMedix said today that it has closed on a Series B equity funding round, raising CHF 3.2 million ($3.62 million) from existing and new investors.

The Zurich-based company, which spun out of the lab of Swiss Federal Institute of Technology researcher Ruedi Aebersold in 2010, plans to use the funds to continue development of its lead product, a protein test for aiding detection of prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.